R Squared’s Bicara Therapeutics BCAX Stock Holding History

R Squared’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,040	Closed	-$18.1K	–	1577
2024 Q4	$18.1K	Buy	+1,040	New	+$21.6K	0.02%	928

Other funds holding BCAX

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

R Squared's BCAX Position: Q1 2025 in Review

R Squared sold out of Bicara Therapeutics (BCAX) in Q1 2025, closing a stake of 1,040 shares — an estimated $18.1K sold.

R Squared first reported a position in BCAX in Q4 2024 and held it in 1 quarter. The position peaked at $18.1K in Q4 2024. 93 funds tracked by Wall St. Rank hold BCAX as of Q1 2025.

R Squared reported no remaining Bicara Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,040 Bicara Therapeutics shares in Q1 2025, an estimated $18.1K.
R Squared first reported a position in Bicara Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Bicara Therapeutics position peaked at $18.1K in Q4 2024.
93 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.